Literature DB >> 19694625

Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states.

M Hondo1, K Nagai, K Ohno, Y Kisanuki, J T Willie, T Watanabe, M Yanagisawa, T Sakurai.   

Abstract

AIM: The effect of orexin on wakefulness has been suggested to be largely mediated by activation of histaminergic neurones in the tuberomammillary nucleus (TMN) via orexin receptor-2 (OX(2)R). However, orexin receptors in other regions of the brain might also play important roles in maintenance of wakefulness. To dissect the role of the histaminergic system as a downstream mediator of the orexin system in the regulation of sleep/wake states without compensation by the orexin receptor-1 (OX(1)R) mediated pathways, we analysed the phenotype of Histamine-1 receptor (H(1)R) and OX(1)R double-deficient (H(1)R(-/-);OX(1)R(-/-)) mice. These mice lack OX(1)R-mediated pathways in addition to deficiency of H(1)R, which is thought to be the most important system in downstream of OX(2)R.
METHODS: We used H(1)R deficient (H(1)R(-/-)) mice, H(1)R(-/-);OX(1)R(-/-) mice, OX(1)R and OX(2)R double-deficient (OX(1)R(-/-);OX(2)R(-/-)) mice, and wild type controls. Rapid eye movement (REM) sleep, non-REM (NREM) sleep and awake states were determined by polygraphic electroencephalographic/electromyographic recording.
RESULTS: No abnormality in sleep/wake states was observed in H(1)R(-/-) mice, consistent with previous studies. H(1)R(-/-);OX(1)R(-/-) mice also showed a sleep/wake phenotype comparable to that of wild type mice, while OX(1)R(-/-); OX(2)R(-/-) mice showed severe fragmentation of sleep/wake states.
CONCLUSION: Our observations showed that regulation of the sleep/wake states is completely achieved by OX(2)R-expressing neurones without involving H(1)R-mediated pathways. The maintenance of basal physiological sleep/wake states is fully achieved without both H(1) and OX(1) receptors. Downstream pathways of OX(2)R other than the histaminergic system might play an important role in the maintenance of sleep/wake states.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19694625      PMCID: PMC3513392          DOI: 10.1111/j.1748-1716.2009.02032.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  40 in total

1.  A detailed mapping of histamine H1-receptors in guinea-pig central nervous system established by autoradiography with [125I]iodobolpyramine.

Authors:  M L Bouthenet; M Ruat; N Sales; M Garbarg; J C Schwartz
Journal:  Neuroscience       Date:  1988-08       Impact factor: 3.590

2.  Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.

Authors:  R M Chemelli; J T Willie; C M Sinton; J K Elmquist; T Scammell; C Lee; J A Richardson; S C Williams; Y Xiong; Y Kisanuki; T E Fitch; M Nakazato; R E Hammer; C B Saper; M Yanagisawa
Journal:  Cell       Date:  1999-08-20       Impact factor: 41.582

3.  Excitatory effect of histamine on EEGs of the cortex and thalamus in rats.

Authors:  K Tasaka; Y H Chung; K Sawada
Journal:  Agents Actions       Date:  1989-04

Review 4.  To eat or to sleep? Orexin in the regulation of feeding and wakefulness.

Authors:  J T Willie; R M Chemelli; C M Sinton; M Yanagisawa
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

5.  Reduced food anticipatory activity in genetically orexin (hypocretin) neuron-ablated mice.

Authors:  Masashi Akiyama; Tomoyo Yuasa; Naomi Hayasaka; Kazumasa Horikawa; Takeshi Sakurai; Shigenobu Shibata
Journal:  Eur J Neurosci       Date:  2004-12       Impact factor: 3.386

6.  A role for lateral hypothalamic orexin neurons in reward seeking.

Authors:  Glenda C Harris; Mathieu Wimmer; Gary Aston-Jones
Journal:  Nature       Date:  2005-08-14       Impact factor: 49.962

7.  Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice.

Authors:  Zhi-Li Huang; Takatoshi Mochizuki; Wei-Min Qu; Zong-Yuan Hong; Takeshi Watanabe; Yoshihiro Urade; Osamu Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

8.  Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins.

Authors:  Tatiana M Korotkova; Olga A Sergeeva; Krister S Eriksson; Helmut L Haas; Ritchie E Brown
Journal:  J Neurosci       Date:  2003-01-01       Impact factor: 6.167

9.  Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.

Authors:  Jon T Willie; Richard M Chemelli; Christopher M Sinton; Shigeru Tokita; S Clay Williams; Yaz Y Kisanuki; Jacob N Marcus; Charlotte Lee; Joel K Elmquist; Kristi A Kohlmeier; Christopher S Leonard; James A Richardson; Robert E Hammer; Masashi Yanagisawa
Journal:  Neuron       Date:  2003-06-05       Impact factor: 17.173

10.  Orexin neurons function in an efferent pathway of a food-entrainable circadian oscillator in eliciting food-anticipatory activity and wakefulness.

Authors:  Michihiro Mieda; S Clay Williams; Christopher M Sinton; James A Richardson; Takeshi Sakurai; Masashi Yanagisawa
Journal:  J Neurosci       Date:  2004-11-17       Impact factor: 6.167

View more
  17 in total

Review 1.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

Review 2.  Current and emerging options for the drug treatment of narcolepsy.

Authors:  Alberto K De la Herrán-Arita; Fabio García-García
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 3.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

4.  Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.

Authors:  Emi Hasegawa; Masashi Yanagisawa; Takeshi Sakurai; Michihiro Mieda
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

5.  Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice.

Authors:  Takatoshi Mochizuki; Elda Arrigoni; Jacob N Marcus; Erika L Clark; Mihoko Yamamoto; Michael Honer; Edilio Borroni; Bradford B Lowell; Joel K Elmquist; Thomas E Scammell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

6.  Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep.

Authors:  Michihiro Mieda; Emi Hasegawa; Yaz Y Kisanuki; Christopher M Sinton; Masashi Yanagisawa; Takeshi Sakurai
Journal:  J Neurosci       Date:  2011-04-27       Impact factor: 6.167

7.  Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study.

Authors:  Yuichi Inoue; Takeshi Watanabe; Shuya Takashima; Takao Takase; Kohei Ishikawa; Naoki Kubota; Jane Yardley; Margaret Moline
Journal:  J Clin Sleep Med       Date:  2021-05-01       Impact factor: 4.062

8.  Differential actions of orexin receptors in brainstem cholinergic and monoaminergic neurons revealed by receptor knockouts: implications for orexinergic signaling in arousal and narcolepsy.

Authors:  Kristi A Kohlmeier; Christopher J Tyler; Mike Kalogiannis; Masaru Ishibashi; Morten P Kristensen; Iryna Gumenchuk; Richard M Chemelli; Yaz Y Kisanuki; Masashi Yanagisawa; Christopher S Leonard
Journal:  Front Neurosci       Date:  2013-12-20       Impact factor: 4.677

9.  Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence.

Authors:  Jonathan A Hollander; Don Pham; Christie D Fowler; Paul J Kenny
Journal:  Front Behav Neurosci       Date:  2012-07-24       Impact factor: 3.558

10.  Differential roles of orexin receptors in the regulation of sleep/wakefulness.

Authors:  Michihiro Mieda; Natsuko Tsujino; Takeshi Sakurai
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-16       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.